The study will enroll approximately 88 patients. Participants will be enrolled in 3 cohorts: 1) Western safety cohort to be enrolled in the US only which will include non-Japanese participants who have metastatic solid tumors with no standard therapeutic alternative, 2) Participants with metastatic pancreatic cancer 3) Participants with metastatic colorectal cancer. All participants will receive: